K
KDT Ventures focuses on early-stage, science-driven startups that are "re-architecting the world at a molecular level" by leveraging cutting-edge chemistry, biology, and computational disciplines. Their strategy involves being an early institutional investor in companies developing revolutionary products and technologies across sectors like therapeutics, digital health, industrial biotechnology, and climate.
73% of their portfolio is in Biotech & Life Sciences. Deal activity increased 200% year-over-year (3 deals in the last 12 months). Average disclosed round size is $44.8M (across 14 rounds with reported amounts).
Portfolio
15
Fund Size
$250M
Top Stage
Series A
Last 12 Mo
3
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
15 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Zag Bio | Series A | $80M | Oct 2025 |
 Faeth Therapeutics | Unknown | $25M | Oct 2025 |
 Arkestro | Growth | $36M | May 2025 |
 March Biosciences | Series A | $28.4M | Oct 2024 |
 ZymoChem | Series A | $21M | Jan 2024 |
| Faeth Therapeutics | Series A | $47M | Jun 2022 |
| VVayyar | Series E | $108M | Jun 2022 |
 Terray Therapeutics | Series A | $60M | Feb 2022 |
| Faeth Therapeutics | Seed | $20M | Jan 2022 |
 54gene | Series B | $25M | Sep 2021 |
 PathAI | Series C | $165M | May 2021 |
| DDebut Biotechnology | Seed | $2.6M | Jan 2020 |
 Ibotta | Series D | — | Aug 2019 |
| 54gene | Seed | $4.5M | Jul 2019 |
 Checkerspot Inc. | Seed | $5M | Jun 2018 |
Top Co-Investors
Digitalis Ventures4 shared
Khosla Ventures3 shared
Future Fund3 shared
S2G Ventures3 shared
Cantos3 shared
Alexandria Venture Investments2 shared
Better2 shared
Agfunder2 shared
Polaris Venture Partners2 shared
Refactor Capital2 shared
Toyota1 shared
GS Futures1 shared
Cavallo Ventures1 shared
Endeavor Catalyst1 shared
Ingressive Capital1 shared
4BIO Capital1 shared
Portal Innovations1 shared
Y Combinator1 shared
Fifty Years1 shared
Unshackled Ventures1 shared
Last updated: 16 April 2026